Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Heise

Showing results (91-100 of 272) with videos related to

Pageof 28
Sort By:
Diabetes, Obesity & Metabolism|March 30, 2007
Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetesO Klein, J Lynge, L Endahl, et al.
Diabetes, Obesity & Metabolism|May 19, 2012
Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetesT Heise, L Hermanski, L Nosek, et al.
Diabetes, Obesity & Metabolism|March 17, 2015
Insulin degludec/insulin aspart produces a dose-proportional glucose-lowering effect in subjects with type 1 diabetes mellitusT Heise, L Nosek, O Klein, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|April 30, 2010
Insulin glulisine has a faster onset of action compared with insulin aspart in healthy volunteersS Arnolds, K Rave, U Hövelmann, et al.
Diabete & Metabolisme|December 1, 1995
Time-action profiles of the intermediate-acting insulin analogue des(64,65)-human proinsulinL Heinemann, T Heise, A Klepper, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|November 11, 2009
Plasma glucose and hypoglycaemia following exercise in people with Type 1 diabetes: a comparison of three basal insulinsV Arutchelvam, T Heise, S Dellweg, et al.
Diabetes, Obesity & Metabolism|April 8, 2015
Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspartT Heise, U Hövelmann, L Brøndsted, et al.
Journal of Virology|February 23, 2007
Complement contributes to inflammatory tissue destruction in a mouse model of Ross River virus-induced diseaseThomas E Morrison, Robert J Fraser, Paul N Smith, et al.
Pediatric Cardiology|January 18, 2003
Afterload reduction therapy in patients following intraatrial baffle operation for transposition of the great arteriesB Robinson, C T Heise, J W Moore, et al.
Diabetes, Obesity & Metabolism|October 15, 2013
Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitusV P Sinha, D C Howey, S L Choi, et al.
Pageof 28

Showing results (91-100 of 272) with videos related to

Sort By:
Pageof 28
Diabetes, Obesity & Metabolism|March 30, 2007
Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetesO Klein, J Lynge, L Endahl, et al.
Diabetes, Obesity & Metabolism|May 19, 2012
Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetesT Heise, L Hermanski, L Nosek, et al.
Diabetes, Obesity & Metabolism|March 17, 2015
Insulin degludec/insulin aspart produces a dose-proportional glucose-lowering effect in subjects with type 1 diabetes mellitusT Heise, L Nosek, O Klein, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|April 30, 2010
Insulin glulisine has a faster onset of action compared with insulin aspart in healthy volunteersS Arnolds, K Rave, U Hövelmann, et al.
Diabete & Metabolisme|December 1, 1995
Time-action profiles of the intermediate-acting insulin analogue des(64,65)-human proinsulinL Heinemann, T Heise, A Klepper, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|November 11, 2009
Plasma glucose and hypoglycaemia following exercise in people with Type 1 diabetes: a comparison of three basal insulinsV Arutchelvam, T Heise, S Dellweg, et al.
Diabetes, Obesity & Metabolism|April 8, 2015
Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspartT Heise, U Hövelmann, L Brøndsted, et al.
Journal of Virology|February 23, 2007
Complement contributes to inflammatory tissue destruction in a mouse model of Ross River virus-induced diseaseThomas E Morrison, Robert J Fraser, Paul N Smith, et al.
Pediatric Cardiology|January 18, 2003
Afterload reduction therapy in patients following intraatrial baffle operation for transposition of the great arteriesB Robinson, C T Heise, J W Moore, et al.
Diabetes, Obesity & Metabolism|October 15, 2013
Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitusV P Sinha, D C Howey, S L Choi, et al.
Pageof 28